Tysabri may deliver 'sustained improvement'

Tysabri may have scored a big plus for drugmakers Biogen Idec and Elan. A trial of the multiple sclerosis treatment showed that it might actually improve the physical disability patients suffer, rather than simply slowing down or staving off decline. "Tysabri-treated patients are significantly more likely to experience a sustained improvement in disability compared to placebo patients," said Frederick Munschauer a neurologist from the State University of New York, adding that, "This [post hoc] analysis represents the first evidence supporting a sustained improvement in function" from an approved MS drug.

That's good news for Biogen and Elan, offering even greater benefit to outweight the risk of a very rare but potentially deadly brain infection that, when it first appeared in Tysabri patients, forced the medication off the U.S. market. Tysabri has since been reintroduced under a risk-management program and continues its comeback story, despite the recent announcement that the infection, primary multifocal leucoencephalopathy, had cropped up again in two patients in Europe.

- see the Biogen release
- read the story in the Irish Times
- get analyst reaction at FinFacts

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.